{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:29:20Z","timestamp":1790310560057,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 drugs who also have a concurrent cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational, multicentre study was conducted, enrolling adult patients with moderate-to-severe plaque psoriasis and a personal history of malignancy. The patients were undergoing any anti-IL-23 treatment approved for psoriasis (guselkumab, risankizumab or tildrakizumab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 198 patients were enrolled. Among these, 67 (33.8%) had a history of malignancy within the past 5\u2005years, whereas 131 (66.2%) had been diagnosed with cancer prior to that time. During the period of the study, six patients (3.0%) experienced progression or recurrence of their existing neoplasia. Moreover, six (3.0%) were diagnosed with a new neoplasia during the study period, discontinuing biologic treatment in only two cases. A subanalysis investigating the relationship between comorbidities and the incidence of neoplastic progression or recurrence during therapy, as well as the development of a new neoplasia, did not show any statistically significant associations. Similarly, significant associations between previous treatments and increased risk of cancer recurrence, progression or development were not found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf184","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:36:50Z","timestamp":1749541010000},"page":"1827-1833","source":"Crossref","is-referenced-by-count":7,"title":["Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study"],"prefix":"10.1093","volume":"50","author":[{"given":"Francesca","family":"Satolli","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma , Parma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gerosa","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma , Parma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Claudio","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Cagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Peccerillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Amerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Brunasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brusasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma , Parma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2025082212470829700_llaf184-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2025082212470829700_llaf184-B2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"2025082212470829700_llaf184-B3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ad.2022.07.021","article-title":"Quality of life and body region affected by psoriasis: a systematic review","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"Suppl. 3","key":"2025082212470829700_llaf184-B4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470829700_llaf184-B5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.14698","article-title":"Cancer risk in 892 089 patients with psoriasis in Korea: a nationwide population-based cohort study","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol"},{"key":"2025082212470829700_llaf184-B6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470829700_llaf184-B7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in The Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025082212470829700_llaf184-B8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/em.21777","article-title":"Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk","volume":"54","author":"Wild","year":"2013","journal-title":"Environ Mol Mutagen"},{"key":"2025082212470829700_llaf184-B9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025082212470829700_llaf184-B10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025082212470829700_llaf184-B11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis","volume":"80","author":"Dhana","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470829700_llaf184-B12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/14712598.2022.2155356","article-title":"Biologics for psoriasis: is there any unmet need left?","volume":"22","author":"Feldman","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025082212470829700_llaf184-B13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470829700_llaf184-B14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ajd.12889","article-title":"Psoriasis and cancer. An Australian\/New Zealand narrative","volume":"60","author":"Rademaker","year":"2019","journal-title":"Australas J Dermatol"},{"key":"2025082212470829700_llaf184-B15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025082212470829700_llaf184-B16","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025082212470829700_llaf184-B17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025082212470829700_llaf184-B18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2025082212470829700_llaf184-B19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"2025082212470829700_llaf184-B20","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2025082212470829700_llaf184-B21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2013.07.004","article-title":"A balance of interleukin-12 and -23 in cancer","volume":"34","author":"Ngiow","year":"2013","journal-title":"Trends Immunol"},{"key":"2025082212470829700_llaf184-B22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470829700_llaf184-B23","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"2025082212470829700_llaf184-B24","doi-asserted-by":"crossref","first-page":"1294416","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"2025082212470829700_llaf184-B25","doi-asserted-by":"crossref","first-page":"17540","DOI":"10.3390\/ijms242417540","article-title":"A multidisciplinary approach to patients with psoriasis and a history of malignancies or on-treatment for solid tumors: a narrative literature review","volume":"24","author":"Denaro","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025082212470829700_llaf184-B26","doi-asserted-by":"crossref","first-page":"2456532","DOI":"10.1080\/09546634.2025.2456532","article-title":"Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study \u2013 IL PSO (Italian landscape psoriasis)","volume":"36","author":"Valenti","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2025082212470829700_llaf184-B27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S0392-0488.18.06202-8","article-title":"Psoriasis and the TNF\/IL23\/IL17 axis","volume":"154","author":"Furue","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"2025082212470829700_llaf184-B28","doi-asserted-by":"crossref","first-page":"adv17752","DOI":"10.2340\/actadv.v103.17752","article-title":"Efficacy and safety of tildrakizumab in older patients: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 244 weeks","volume":"103","author":"Ter Haar","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2025082212470829700_llaf184-B29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5\u2005years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025082212470829700_llaf184-B30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5\u2005years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470829700_llaf184-B31","doi-asserted-by":"crossref","first-page":"670398","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: clinical evidence and possible mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol"},{"key":"2025082212470829700_llaf184-B32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14712598.2025.2471093","article-title":"Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"25","author":"Bruni","year":"2025","journal-title":"Expert Opin Biol Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf184\/63498362\/llaf184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1827\/63498362\/llaf184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1827\/63498362\/llaf184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:17Z","timestamp":1755881237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1827\/8163657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf184","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,16]]}}}